Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Lok AS, et al. Among authors: morishima c. Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1. Gastroenterology. 2011. PMID: 21129375 Free PMC article. Clinical Trial.
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Shiffman ML, et al. Among authors: morishima c. Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947. doi: 10.1053/j.gastro.2004.01.014. Gastroenterology. 2004. PMID: 15057741 Clinical Trial.
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Lee WM, et al. Among authors: morishima c. Control Clin Trials. 2004 Oct;25(5):472-92. doi: 10.1016/j.cct.2004.08.003. Control Clin Trials. 2004. PMID: 15465617 Clinical Trial.
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.
Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR; HALT-C Trial Group. Polyak SJ, et al. Among authors: morishima c. Virol J. 2005 Apr 22;2:41. doi: 10.1186/1743-422X-2-41. Virol J. 2005. PMID: 15847697 Free PMC article.
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Morishima C, et al. J Infect Dis. 2006 Apr 1;193(7):931-40. doi: 10.1086/500952. Epub 2006 Feb 22. J Infect Dis. 2006. PMID: 16518754 Clinical Trial.
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group. Bonkovsky HL, et al. Among authors: morishima c. Gastroenterology. 2006 Nov;131(5):1440-51. doi: 10.1053/j.gastro.2006.08.036. Epub 2006 Aug 18. Gastroenterology. 2006. PMID: 17101320 Clinical Trial.
96 results